Literature DB >> 9767749

The histo-blood group ABO system and tissue transplantation.

T Eastlund1.   

Abstract

In general, one might expect that ABO incompatibility of donor and recipient would be important to some degree if viability of the transplanted allograft is important for graft incorporation and function. This is true for some recipients of organs. However, ABO incompatibility appears to play a minor role, if any, in the clinical success of viable cornea and viable skin allografts. Even though A and B antigens may be present on the transplanted tissue, other factors that can contribute include the strength of the immune response, the avidity of the antibody, and the dose of the antigen presented, which may vary from donor to donor. Although A and B antigens are present on endothelium, the use of ABO-incompatible heart valves is successful, as they carry out their mechanical function by using the strength of the connective tissue rather than the viability of the donor endothelium. The presence, immunogenicity, and significance of A and B antigens in human vessel transplants have not been well studied. With the more commonly transplanted tissue, such as bone and tendon, posttransplant success does not depend on cellular viability or ABO compatibility.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9767749     DOI: 10.1046/j.1537-2995.1998.381098440863.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  29 in total

Review 1.  Beyond immunohaematology: the role of the ABO blood group in human diseases.

Authors:  Giancarlo Maria Liumbruno; Massimo Franchini
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

2.  Blood group distribution and life-expectancy: a single-centre experience.

Authors:  Carlo Mengoli; Carlo Bonfanti; Chiara Rossi; Massimo Franchini
Journal:  Blood Transfus       Date:  2014-10-29       Impact factor: 3.443

3.  ABO blood groups in relation to breast carcinoma incidence and associated prognostic factors in Moroccan women.

Authors:  S Zouine; F Marnissi; N Otmani; M Bennani Othmani; M El Wafi; K Kojok; Y Zaid; N Tahiri Jouti; N Habti
Journal:  Med Oncol       Date:  2016-05-30       Impact factor: 3.064

4.  ABO blood group and risk of coronary heart disease in two prospective cohort studies.

Authors:  Meian He; Brian Wolpin; Kathy Rexrode; Joann E Manson; Eric Rimm; Frank B Hu; Lu Qi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-08-14       Impact factor: 8.311

5.  Evaluation of ABO blood groups and blood-based biomarkers as a predictor of growth kinetics of renal angiomyolipoma.

Authors:  Burak Arslan; Okan Gürkan; Bugra Çetin; Öykü Aksoy Arslan; Taha Göv; Gökhan Yazıcı; Tolga Eroglu; Mustafa Asım Avcı; Enver Ozdemir
Journal:  Int Urol Nephrol       Date:  2018-10-15       Impact factor: 2.370

6.  ABO blood group in aneurysmal subarachnoid haemorrhage-a pilot study.

Authors:  Oliver Richards; Kirsten J Cromie; Christopher Akhunbay-Fudge; Neeraj Kalra; Richard G Feltbower; Paul Chumas; Ian A Anderson
Journal:  Acta Neurochir (Wien)       Date:  2022-01-18       Impact factor: 2.216

7.  Reference glycan structure libraries of primary human cardiomyocytes and pluripotent stem cell-derived cardiomyocytes reveal cell-type and culture stage-specific glycan phenotypes.

Authors:  Christopher Ashwood; Matthew Waas; Ranjuna Weerasekera; Rebekah L Gundry
Journal:  J Mol Cell Cardiol       Date:  2020-01-21       Impact factor: 5.000

Review 8.  The prognostic value of ABO blood group in cancer patients.

Authors:  Massimo Franchini; Giancarlo M Liumbruno; Giuseppe Lippi
Journal:  Blood Transfus       Date:  2015-11-06       Impact factor: 3.443

9.  ABO blood groups and rheumatic diseases.

Authors:  Songül Çildağ; Yasemin Kara; Taşkın Şentürk
Journal:  Eur J Rheumatol       Date:  2017-11-02

10.  ABO and RhD Blood Groups in Nasal Polyposis.

Authors:  Boris Jelavic; Josipa Marković; Sanja Klarić; Marko Martinac; Sanja Selak; Tomislav Baudoin
Journal:  Turk Arch Otorhinolaryngol       Date:  2018-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.